Published on: Jan 28, 2026
Recent research has expanded understanding of cannabis and its primary psychoactive compound, Δ⁹-tetrahydrocannabinol (THC), revealing potential medical benefits such as anti-inflammatory and neuroprotective effects. However, THC’s known negative impact on learning and memory has limited its clinical application in neurological disorders. A new study led by Dr. Chu Chen at The University of Texas Health Science Center at San Antonio suggests that combining THC with the selective anti-inflammatory drug celecoxib may overcome these limitations.
In mouse models of Alzheimer’s disease, low-dose THC paired with celecoxib improved cognitive performance, reduced beta-amyloid and tau pathology, and decreased neuroinflammation more effectively than THC alone. The researchers found that THC unexpectedly increases COX-2 activity in the brain, contributing to memory impairment, while celecoxib counteracts this inflammatory response without eliminating THC’s beneficial effects. Importantly, both drugs are already FDA-approved, offering a potential fast track to clinical trials.
The findings highlight a promising combination therapy approach that could help prevent or delay Alzheimer’s disease onset, bringing cannabis-based treatments closer to safe and effective clinical use in neurodegenerative disorders.
Back to News
Empowering Innovation Through Global Conferences and Events.
© 2025 SciInov. All Rights Reserved.